TICKERNERD
Menu
GNPXGNPXHealthcare · Biotechnology

GNPX Stock Forecast: Genprex, Inc. Price Predictions for 2026-2027

Last close, 31 July 2026
$5.99

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 1 Aug 2026 — in the weakest quartile.

Market cap
$3.0M
Ticker Nerd rank
11 / 100
Median analyst target
—
Analysts covering
1
Ticker Nerd rank

GNPX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Genprex, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Accruals
47
Growth
43
Volatility
31
Revisions
25
Issuance
23
Quality
17
Value
7
Momentum
2

Size (98): Smaller than most of the companies we track.

Momentum (2): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Genprex, Inc. — and when they’d sell — is the membership.

Wall Street

GNPX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GNPX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 May 2024HC Wainwright & Co.ReiteratesBuy$10
15 May 2024HC Wainwright & Co.ReiteratesBuy$10
4 Apr 2024HC Wainwright & Co.ReiteratesBuy—
3 Apr 2024HC Wainwright & Co.ReiteratesBuy—
25 Mar 2024HC Wainwright & Co.InitiatesBuy—
30 Jan 2023Dawson JamesInitiatesBuy$3.00
14 Sept 2018Maxim GroupInitiatesBuy$5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

GNPX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Genprex, Inc. (GNPX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
0.1×

Cheaper than 90% of US stocks

EV / EBITDA
1.0×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−160.8%

Higher than 8% of US stocks

Return on assets
−76.2%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

GNPX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GNPXGenprex, Inc.$3.0M
11
ONCOOnconetix, Inc.$3.1M
16
SXTP60 Degrees Pharmaceuticals, Inc.$3.1M
25
CELZCreative Medical Technology Holdings, Inc.$3.1M
35
ARTLArtelo Biosciences, Inc.$2.7M
15
LABTLakewood-Amedex Biotherapeutics, Inc.$3.5M
23
PPCBPropanc Biopharma, Inc.$3.5M
43
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GNPX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest GNPX news & analysis

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

PRNewsWire · 3 Aug 2026positive

Genprex announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Building on promising preclinical and clinical data, the collaboration intends to use TROP2 as a biomarker to refine patient identification and optimize trial selection criteria.

Why it matters — The collaboration with Roche could help refine biomarker-driven patient selection, potentially advancing Genprex's precision-medicine approach in its NSCLC clinical program.

FAQ

Frequently asked questions about GNPX stock

Is GNPX stock a buy right now?

Of the 1 analysts covering Genprex, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Genprex, Inc. 11 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GNPX?

As at 1 Aug 2026, Genprex, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the GNPX stock forecast for 2030?

No analyst covering Genprex, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GNPX are extrapolating price history, which says nothing about the business.

What does Genprex, Inc. do?

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes.

What is the latest news on GNPX?

The most recent item we track (PRNewsWire, 3 Aug 2026): "Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies". Genprex announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Building on promising preclinical and clinical data, the collaboration intends to use TROP2 as a biomarker to refine patient identification and optimize trial selection criteria.

Company

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The company's technologies deliver disease-fighting genes to address unmet needs in these patient populations. Its oncology program employs the systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to encapsulate gene-expressing plasmids targeting cancer cells. The lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is under evaluation in clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with programs receiving FDA Fast Track and Orphan Drug designations. For diabetes, Genprex advances GPX-002, utilizing an AAV vector to deliver Pdx1 and MafA genes to the pancreas; in Type 1 diabetes, it transforms alpha cells into insulin-producing beta-like cells that evade immune detection, while in Type 2, it rejuvenates exhausted beta cells. Recent efforts include licensing additional technologies for glioblastoma treatment and advancing diabetes research with non-viral delivery systems. Founded in 2009 and headquartered in Austin, Texas, Genprex collaborates with leading institutions to expand its gene therapy pipeline in oncology and endocrinology.

CEO Mr. Ryan M. Confer M.S. · 13 employees · United States · https://www.genprex.com